
July 8, 2024
Breakthrough in Alzheimer’s: FDA Approves Donanemab by Eli Lilly
The U.S. Food and Drug Administration (FDA) has approved a new drug called donanemab for the treatment of early symptomatic Alzheimer’s disease. This significant development brings hope to many patients and their families. Developed by Eli Lilly, a pharmaceutical company
- 76
- 0
- 0